Edition:
United States

GW Pharmaceuticals PLC (GWPH.OQ)

GWPH.OQ on NASDAQ Stock Exchange Global Market

123.98USD
3:59pm EST
Change (% chg)

$1.66 (+1.36%)
Prev Close
$122.32
Open
$123.92
Day's High
$124.72
Day's Low
$122.57
Volume
46,124
Avg. Vol
108,270
52-wk High
$136.93
52-wk Low
$92.77

Chart for

About

GW Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing therapeutics from its cannabinoid product platform in a range of disease areas. The Company's lead cannabinoid product candidate is Epidiolex, which is a liquid formulation of pure plant-derived cannabidiol (CBD). The Company offers... (more)

Overall

Beta: 2.69
Market Cap(Mil.): $3,103.54
Shares Outstanding(Mil.): 2.11
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 188.50 15.25
EPS (TTM): -- -- --
ROI: -- -11.67 33.27
ROE: -- -36.21 16.35

BRIEF-GW Pharmaceuticals Reacquires Full Rights To Develop And Commercialize Sativex In U.S.

* GW PHARMACEUTICALS REACQUIRES FULL RIGHTS TO DEVELOP AND COMMERCIALIZE SATIVEX® IN U.S.

7:16am EST

BRIEF-GW Pharmaceuticals Announces Pricing Of Public Offering Of ADSs Raising Gross Proceeds Of $276 Million

* GW PHARMACEUTICALS PLC ANNOUNCES PRICING OF PUBLIC OFFERING OF ADSS RAISING GROSS PROCEEDS OF $276 MILLION

Dec 06 2017

BRIEF-GW Pharmaceuticals Announces Proposed Public Offering Of ADSs

* GW PHARMACEUTICALS ANNOUNCES PROPOSED PUBLIC OFFERING OF ADSS

Dec 05 2017

Zogenix stock soars on epilepsy drug trial success

Zogenix Inc's experimental treatment for a rare form of epilepsy met the main goal in a late-stage study, the company said on Friday, more than doubling the value of its shares and hurting those of peer GW Pharmaceuticals .

Sep 29 2017

UPDATE 3-Zogenix stock soars on epilepsy drug trial success

* Analyst expects drug to become standard in Dravet treatment

Sep 29 2017

BRIEF-GW Pharmaceuticals reports Q3 results

* Gw Pharmaceuticals reports fiscal third quarter 2017 financial results and operational progress Source text for Eikon: Further company coverage:

Aug 07 2017

Earnings vs. Estimates